

Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung

MAKOTO NAKAGAWA, HIDETAKA URAMOTO, HIDEHIKO SHIMOKAWA,
TAKAMITSU ONITSUKA, TAKESHI HANAGIRI and FUMIHIRO TANAKA

Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

Received February 25, 2011; Accepted April 15, 2011

DOI: 10.3892/etm.2011.258

Abstract. Not all patients with lung cancer require postoperative adjuvant chemotherapy after a complete resection. However, no useful markers exist for either selecting appropriate candidates or for predicting clinical recurrence. The purpose of the present study was to clarify the clinical role of insulin-like growth factor receptor-1 (IGFR1) in lung adenocarcinoma. Tumor specimens were collected from 182 patients who underwent a complete resection for adenocarcinoma of the lung. The expression of IGFR1 was evaluated by immunohistochemistry. The genetic status of the epidermal growth factor receptor (EGFR) and K-ras genes was also investigated by PCR-based analyses. Immunohistochemistry and real-time PCR assays were used to evaluate the MET gene association with tyrosine phosphorylation and hepatocyte growth factor (HGF) status, and amplification, respectively. Positive expression of IGFR1 was detected in 43 (23.6%) of the 182 cases. A positive IGFR1 expression was also identified in 12 (42.9%) and 31 (20.1%) of the patients with and without recurrence, respectively ($p=0.009$). Logistic regression models indicated that positive staining for IGFR1 expression was an independent factor associated with tumor recurrence. IGFR1 expression was associated with a poorer disease-free survival (DFS). Multivariate analysis demonstrated positive IGFR1 expression to be independently associated with an increased risk for poor DFS. The tumors appearing positive for IGFR1 were more frequent among those with K-ras mutations when

compared with the wild-type group. IGFR1 expression was associated with reduced DFS correlating with postoperative recurrence. Therefore, the expression status of IGFR1 can be a candidate surrogate marker to select patients who may benefit from adjuvant chemotherapy.

Introduction

Lung cancer is the leading cause of cancer-related death in the world (1). The incidence of adenocarcinoma, one of the major histological subtypes of non-small cell lung cancer (NSCLC), is increasing (2). The prognosis is dismal as the 5-year survival is only approximately 50%, even in patients who achieve complete surgical resection (3). This suggests that occult metastases are present at the time of surgical intervention. As a consequence, adjuvant chemotherapy is required (4). However, the 5-year survival rate of patients with resected stage IB NSCLC is 74% without adjuvant chemotherapy, suggesting that not all patients require chemotherapy after a complete resection (5). Therefore, it is necessary to identify patients who may benefit the most from post-operative adjuvant chemotherapy to, not only precisely select the patients who require additional treatment, but also to prevent the occurrence of adverse events in patients who do not require treatment (4). Therefore, it is important to evaluate the biological and molecular characteristics of lung adenocarcinoma to identify the factors related to recurrence following surgery. However, there are currently no useful markers that predict clinical recurrence.

Insulin-like growth factor receptor-1 (IGFR1) is a transmembrane heterotetrameric protein implicated in promoting oncogenic transformation, growth and survival of cancer cells (6). The binding of insulin-like growth factor (IGF) to the extracellular domain of IGFR1 activates the tyrosine kinase activity of IGFR1 and triggers a cascade of reactions involving signal transduction pathways (7). The overexpression of IGFR1 has been shown to correlate with a poor prognosis in NSCLC patients (8). However, the precise reason for the poor prognosis remains unclear. Therefore, we hypothesized that IGFR1 may be a useful indicator of tumor recurrence in patients following complete resection. This is the first molecular analysis of the IGFR1 status and tumor recurrence related to the disease-free survival (DFS) of patients with lung adenocarcinoma, and association of EGFR-related molecules.

Correspondence to: Dr Hidetaka Uramoto, Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan
E-mail: hidetaka@med.uoeh-u.ac.jp

Abbreviations: IGFR1, insulin-like growth factor receptor-1; EGFR, epidermal growth factor receptor; HGF, hepatocyte growth factor; DFS, disease free survival; NSCLC, non-small cell lung cancer; IGF, insulin-like growth factor; IHC, immunohistochemical; 95% CI, 95% confidence interval; OR, odds ratio

Key words: insulin-like growth factor receptor-1, recurrence, lung cancer, adenocarcinoma

Materials and methods

Patients, clinical features and follow-up. Tumor samples were obtained from 296 patients with primary lung adenocarcinoma who had undergone a surgical resection between 2003 and 2007 at the Second Department of Surgery. Nine of these patients were stage IV and 25 underwent an incomplete resection. The tumor samples from 80 patients were too small to evaluate by immunohistochemical (IHC) staining. As a result, 114 patients were excluded from further analysis and 182 tumor specimens were evaluated. All the patients were Japanese, including 100 males and 82 females in this series, with a mean age of 68.5 years (range 23-88). No patients had received either chemotherapy or radiotherapy prior to the resection. There were 75 never smokers, 50 former and 57 current smokers. Former smokers were defined as those who quit smoking at least 3 years before the time of surgery. The tumor stage was classified according to the TNM Classification for Lung Cancer (7th edition) (9). According to the pathological stage, 105 patients had tumors of stage IA, 39 of IB, 13 of IIA, 6 of IIB, 16 of IIIA and 3 of stage IIIB.

The patients were followed up every month during the first postoperative year and at approximately 2- to 4-month intervals thereafter. The evaluations included a physical examination, chest roentgenography, an analysis of blood chemistry and measurements of tumor markers, such as CEA, SCC and CYFRA. Chest and abdominal computed tomography, brain magnetic resonance imaging and a bone scintiscan were performed every 6 months for 3 years after surgery. Additional examinations were performed when any symptoms or signs of recurrence were detected. Twenty-seven (14.8%) patients received adjuvant chemotherapy, 18 received carboplatin plus paclitaxel, 7 received carboplatin plus gemcitabine and 2 received tegafur-uracil. A follow-up was conducted in all patients, and the median follow-up period was 68.7 months. One hundred and forty-three patients were alive and free of cancer at the last follow-up, while 11 patients had died of other causes without evidence of cancer, 12 patients were alive with recurrent cancer and 16 patients had died of cancer.

Immunohistochemical staining and evaluation for IGFR1. The institutional review board approved the study protocol, and informed consent for the use of the tumor specimens was obtained either from the patients or from the patients' legal guardians. IHC staining was conducted using serial sections from the same paraffin-embedded blocks according to previously described methods (10,11). All specimens were stained with H&E for the histological diagnosis. Briefly, the sections were placed in 0.01 mol/l citrate buffer (pH 6.0) and autoclaved at 121°C for 10 min. They were treated with 3% H₂O₂ for 5 min to block the endogenous peroxidase activity. The primary antibody used was a mouse monoclonal antibody against human IGFR1 (3C8B1; Abcam, Cambridge, MA, USA) (12), diluted 1:500 in PBS and incubated for 18 h at 4°C. Thereafter, IHC staining was performed by the labeled polymer method (Histofine Simple Stain MAX-PO kit; Nichirei, Tokyo, Japan) according to the manufacturer's instructions (13,14). The positive and negative controls were




Figure 1. Representative IHC staining. (A) Positive staining for IGFR1 with brown-stained membrane is viewed at low power (original magnification, x100). (B) Negative staining for IGFR1 is shown.

processed using primary lung squamous cell carcinoma specimens expressing IGFR1 and by the exclusion of the primary antibody, respectively. IHC was considered to be positive only when a distinct cell membrane staining was evident (Fig. 1A). An average of 1,500 cells were evaluated per section utilizing a semi-quantitative grading system based on four stages: 0, no staining; 1+, staining in 1-10% of the cells; 2+, staining in 11-25% of the cells; 3+, staining in >25% of the cells. A cutoff value of 10% positive cells (stages of 2+ and 3+) was used in order to avoid inclusion of scattered positivity of the same intensity found in the normal bronchial tissue (15). The slides were independently examined by two of the investigators (M.N. and H.S.) who were blinded to the clinicopathological data. Any discrepancy between the two investigators was resolved by their simultaneous examination using a double-headed microscope. The correlation of IGFR1 status and the genetic factors included below were also analyzed.

Detection and quantification of EGFR-related signaling molecules. The genomic DNA was extracted from each tumor by previously described methods (16). The EGFR and K-ras mutations were investigated by PCR-based analyses (13). The status of phosphorylation of MET and HGF was examined by

Table I. Relationship between the IGF1R expression and clinicopathological characteristics.

Variables	No. of patients	IGF1R expression	
		Positive n (%)	Negative n
Total patients	182	43 (23.6)	139
Gender			
Male	100	25 (25.0)	75
Female	82	18 (22.0)	64
Age (years)			
<68	74	18 (24.3)	56
≥68	108	25 (23.1)	83
Pathologic stage			
IA	105	24 (22.9)	81
IB-III	77	19 (24.7)	58
T status			
T1a	76	19 (25.0)	57
T1b-4	106	24 (22.6)	82
N status			
Negative	151	33 (21.9)	118
Positive	31	10 (32.3)	21
Smoking history			
Never	75	18 (24.0)	57 ^b
Former	50	11 (22.0)	39
Current	57	14 (24.6)	43
Tumor grade ^a			
G1	94	20 (21.3)	74 ^c
G2	59	16 (27.1)	43
G3	15	3 (20.0)	12
CEA ^c			
<2.5	123	28 (22.8)	95
≥2.5	57	15 (26.3)	42
SCC ^a			
<1.5	140	34 (24.3)	106
≥1.5	28	5 (17.9)	23
CYFRA ^a			
<2.0	104	24 (23.1)	80
≥2.0	74	19 (25.7)	55

^aUnclassified patients were excluded; ^bnever vs. former/current; ^cG1 vs. G2-3.

IHC staining (13). The MET gene copies were determined by real-time PCR assays (13).

Statistical analyses. Statistical associations were determined by the χ^2 test or Fisher's exact test. A multivariate logistic regression was used to evaluate independent associations. DFS and 95% confidence intervals (95% CI) were evaluated by the Kaplan-Meier method comparing the different groups by log-rank test. The Cox proportional hazards model was applied to the multivariate survival analysis. The odds ratio (OR) was calculated for each variable. The statistical difference was

Table II. Recurrent sites of tumors.

	Site	No. ^a
Hematogenous (n=25) ^b	Lung	10
	Brain	9
	Bone	5
	Adrenal	1
Locoregional (n=8) ^b	Lymph node	5
	Pleural dissemination	3

^aThe numbers of recurrent sites overlapped. ^bTwo, one, one and one subject had recurrent tumors in both the brain and bone, brain and adrenal, brain and pleural dissemination, and bone and lymph nodes, respectively.

Table III. Relationship between IGF1R expression and recurrence.

Variables	IGF1R expression	
	Positive n (%)	Negative
Cases with recurrence	12 (42.9)	16
Cases without recurrence	31 (20.1)	123

considered to be significant at $p < 0.05$. The data were analyzed with the Abacus Concepts, Survival Tools for Stat View software package (Abacus Concepts, Inc., Berkeley, CA, USA).

Results

Detection of IGFR1 expression and clinicopathological characteristics. Positive expression of IGFR1 was identified in 43 (23.6%) of the 182 patients. There was no significant association between IGFR1 expression and the clinical factors (Table I).

Relationship between IGFR1 expression and recurrence. The majority of the first sites of tumor recurrence were hematogenous metastases. Twenty-five and 8 cases had hematogenous (10, lung; 9, brain; 5, bone; 1, adrenal metastasis) and locoregional (4, lymph node metastasis; 3, pleural dissemination) recurrences, respectively (Table II). The positive expression of IGFR1 was identified in 12 (42.9%) of 28 patients and 31 (20.1%) of 154 patients with and without recurrence, respectively ($p = 0.009$; Table III). The univariate and multivariate logistic regression models indicated that expression of IGFR1 was an independent predictor for recurrence, as were young age and N status (Tables IV and V).

Influence of IGFR1 expression and clinicopathological factors on DFS. The detectable relative risk was estimated to be 2.0 with 90% statistical power. The 5-year DFS rate in patients with negative and positive IGFR1 expression was 87.6 and 70.7%, respectively ($p = 0.007$). Positive IGFR1 expression

Table IV. Univariate analysis of the factors contributing to recurrence.

Variables	Odds ratio	95% confidence interval	p-value
Gender: male	1.322	0.581-3.008	0.506
Age: <68 years	2.630	1.151-6.007	0.022
Smoking history: former + current	1.582	0.673-3.717	0.292
T status: 1b-4	3.056	1.174-7.955	0.022
N status: positive	9.952	4.025-24.609	<0.001
Tumor grade: G2-3	6.149	2.171-17.415	<0.001
IGF1R expression: positive	2.976	1.277-6.934	0.012

Table V. Multivariate analysis of the factors contributing to recurrence.

Variables	Odds ratio	95% confidence interval	p-value
Gender: male	1.444	0.291-7.160	0.653
Age: <68 years	3.981	1.461-10.851	0.007
Smoking history: former + current	1.076	0.210-5.556	0.927
T status: 1b-4	2.630	0.870-7.949	0.087
N status: positive	10.319	3.623-29.389	<0.001
IGF1R expression: positive	3.153	1.150-8.648	0.026

Table VI. Univariate analysis using a proportional hazards model for disease-free survival.

Variables	Characteristics		95% confidence interval	Hazard ratio	p-value
	Unfavorable	Favorable			
Gender	Male	Female	0.613-2.793	1.309	0.488
Age (years)	<68	≥68	1.082-4.934	2.311	0.031
Smoking history	Former + Current	Never	0.709-3.472	1.567	0.267
T status	1b-4	1a	1.180-7.184	2.912	0.020
N status	Positive	Negative	3.704-16.667	7.874	<0.001
Tumor grade	G2-3	G1	2.104-15.123	5.642	<0.001
IGF1R expression	Positive	Negative	1.269-5.682	2.681	0.001




Figure 2. Kaplan-Meier DFS curves stratified by IGF1R expression. The heavy and narrow lines indicate positive and negative expression of IGF1R, respectively.

was associated with a poorer DFS according to the univariate survival analysis (Fig. 2) ($p=0.001$; Table VI). A multivariate survival analysis also demonstrated that positive IGF1R expression was independently associated with an increased risk for a poor DFS ($p=0.020$; Table VII).

Relationship between IGF1R and molecular markers. EGFR and K-ras mutations were identified in 63 (34.6%) and 17 (9.3%) patients in these series, respectively. P-MET 1234/1235 and HGF were identified in 12 (6.6%) and 104 (57.1%) patients, respectively. MET amplification was identified only in 8 patients (4.4%). There was no significant association of positive IGF1R expression with the EGFR mutation, an overexpression of p-MET 1234/1235 and HGF, and MET amplification. There were significantly more tumors with

Table VII. Multivariate analysis using a proportional hazards model for disease-free survival.

Variables	Characteristics		95% confidence interval	Hazard ratio	p-value
	Unfavorable	Favorable			
Gender	Male	Female	0.317-3.650	1.076	0.906
Age (years)	<68	≥68	1.222-5.686	2.636	0.014
Smoking history	Former + Current	Never	0.318-4.132	1.147	0.835
T status	1b-4	1a	0.955-6.095	2.412	0.063
N status	Positive	Negative	2.959-14.286	6.494	<0.001
IGF1R expression	Positive	Negative	1.157-5.435	2.506	0.020

Table VIII. Association among molecular markers.

Variables	No. of patients	IGF1R expression	
		Positive n (%)	Negative n
Total patients	182	43 (23.6)	139
EGFR mutation			
Mutated	63	17 (27.0)	46
Wild-type	119	26 (21.8)	93
K-ras mutation			
Mutated	17	8 (47.1)	9
Wild-type	165	35 (21.2)	130
p-MET			
Positive	12	4 (33.3)	8
Negative	170	39 (22.9)	131
MET amplification			
Positive	8	0 (0.00)	8
Negative	174	43 (24.7)	131
HGF expression			
Positive	104	25 (24.0)	79
Negative	78	18 (23.1)	60

IGF1R expression among those with the K-ras mutation when compared with the wild type group ($p=0.017$; Table VIII).

Discussion

The present study revealed two significant findings. First, an increased expression of IGF1R was significantly correlated with postoperative recurrence. Furthermore, positive IGF1R expression was associated with a poorer DFS, thus suggesting a more aggressive tumor behavior. This finding suggests that IGF1R expression is a suitable biomarker with which to identify those candidates who may benefit most from adjuvant chemotherapy in adenocarcinoma following a complete resection. Notably, metastatic NSCLC patients treated with gefitinib with high levels of IGF1R expression survived longer than such patients lacking expression of the protein (17). Collectively, this trend for IGF expression, similar to

Her2 status, is both a poor prognostic marker in untreated patients and a favorable predictive marker for treated patients, suggesting IGF1R as a good molecular target. In fact, the clinical benefit of an anti-IGF1R antibody has been demonstrated in a phase II clinical study (18). The prognostic impact of IGF1R remains controversial. Merrick *et al* showed that high IGF1R-1 expression indicated a poor prognosis in a cohort of surgically treated NSCLC patients (8), which was consistent with the present data. On the other hand, others reported that IGF1R-1 protein expression alone was not significantly associated with survival (15,19). The discrepancy between these findings may be due to the number of patients analyzed, homogeneity, such as a different pathological stage, histology and the method used for IHC.

Secondly, a significant correlation was observed between positive expression of IGF1R and K-ras mutation. These results suggest that a correlation exists between the expression status of IGF1R and EGFR signaling, including the K-ras pathway (20,21). Shen *et al* reported that the combination of both K-ras and IGF1R antisense oligodeoxynucleotide cooperatively inhibited the growth of pancreatic cancer cell lines *in vitro*, and induced their apoptosis *in vivo* (22). Furthermore, combined IGF-1 and K-ras analyses have been shown to be beneficial for the better selection of colorectal cancer patients that may respond to therapy (23). Therefore, a new strategy to co-target both IGF1R-1 and K-ras may be required to control lung cancers expressing IGF1R with the K-ras mutation.

In conclusion, the present results revealed that the incidence of IGF1R overexpression was significantly higher in recurrent cases than in non-recurrent ones. Furthermore, IGF1R overexpression was also associated with poorer DFS. The present results therefore indicate that IGF1R expression may be a useful marker for predicting postoperative recurrence in patients with lung adenocarcinoma following surgery.

Acknowledgements

The authors thank Misako Fukumoto and Yukiko Koyanagi for the valuable technical assistance. This study was supported, in part, by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.

References

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. *CA Cancer J Clin* 55: 74-108, 2005.
2. Janssen-Heijnen ML and Coebergh JW: Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. *Lung Cancer* 31: 123-137, 2001.
3. Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T and Miyaoka E: The Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. *Lung Cancer* 50: 227-234, 2005.
4. Pignon JP, Tribodet H, Scagliotti GV, *et al*: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol* 26: 3552-3559, 2008.
5. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and Ohta M: Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. *N Engl J Med* 350: 1713-1721, 2004.
6. Khandwala HM, McCutcheon IE, Flyvbjerg A and Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. *Endocr Rev* 21: 215-244, 2000.
7. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. *Cancer Lett* 195: 127-137, 2003.
8. Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A, Rzyman W, Jassem E, Jassem J, Franklin WA, Bunn PA and Hirsch FR: High insulin-like growth factor 1 receptor (IGF 1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients. *J Clin Oncol* 25: 7550, 2007.
9. Vallières E, Shepherd FA, Crowley J, van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 4: 1049-1059, 2009.
10. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. *Lung Cancer* 68: 198-203, 2010.
11. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, Takenoyama M, Hanagiri T, Oyama T and Yasumoto K: Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. *Lung Cancer* 70: 320-328, 2010.
12. Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K and Ahn MJ: Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. *APMIS* 117: 861-869, 2009.
13. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. *J Thorac Oncol* 5: 591-596, 2010.
14. Shimokawa H, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K and Hanagiri T: TS expression predicts postoperative recurrence in adenocarcinoma of the lung. *Lung Cancer*: Oct. 21, 2010 (E-pub ahead of print).
15. Ludovini V, Bellezza G, Pistola L, *et al*: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. *Ann Oncol* 20: 842-849, 2009.
16. Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, Hanagiri T, Morita M and Yasumoto K: Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. *Lung Cancer* 51: 71-77, 2006.
17. Cappuzzo F, Toschi L, Tallini G, *et al*: Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. *Ann Oncol* 17: 1120-1127, 2006.
18. Karp DD, Paz-Ares LG, Novello S, *et al*: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. *J Clin Oncol* 27: 2516-2522, 2009.
19. Cappuzzo F, Tallini G, Finocchiaro G, *et al*: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. *Ann Oncol* 21: 562-567, 2010.
20. Lee AV, Cui X and Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. *Clin Cancer Res* 7: 4429-4435, 2001.
21. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ and Streuli CH: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. *J Biol Chem* 277: 27643-27650, 2002.
22. Shen YM, Yang XC, Yang C and Shen JK: Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides. *World J Gastroenterol* 14: 5176-5185, 2008.
23. Scartozzi M, Mandolesi A, Giampieri R, *et al*: Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab and irinotecan. *Int J Cancer* 127: 1941-1947, 2010.